What Does Montelukast Treat? Asthma, Allergies & More

Montelukast is a prescription medication approved to treat three related conditions: chronic asthma, seasonal and year-round allergic rhinitis (hay fever), and exercise-induced bronchoconstriction (the airway narrowing that some people experience during physical activity). It works by blocking the action of leukotrienes, inflammatory molecules your body releases during allergic and asthmatic reactions. Beyond those approved uses, doctors sometimes prescribe it off-label for a handful of other conditions, and researchers are exploring applications that would have seemed far-fetched when the drug first hit the market in the late 1990s.

How Montelukast Works

When your body encounters an allergen or an asthma trigger, certain immune cells release chemicals called cysteinyl leukotrienes. These molecules cause smooth muscle around your airways to tighten, ramp up mucus production, and make the lining of your airways swell. Montelukast blocks the receptor those leukotrienes latch onto, which dials down all three of those responses at once.¹ That is a narrower mechanism than corticosteroids, which dampen inflammation through multiple pathways. It also means montelukast is not a rescue drug. You would not grab it during an acute asthma attack the way you would reach for a quick-acting inhaler. Its strength is in daily prevention.

Chronic Asthma

Montelukast’s longest-standing use is for ongoing asthma management. In clinical trials, a daily 10 mg dose in adults improved lung function, reduced daytime symptoms, and cut the need for rescue inhaler puffs compared with placebo.² In children, the evidence is similarly favorable for mild-to-moderate disease, and the drug is often considered when a child cannot or will not use an inhaler properly, or when parents are concerned about corticosteroid side effects such as slowed growth.³

That said, montelukast is generally not the first choice for persistent asthma. Inhaled corticosteroids remain the recommended front-line treatment because they control inflammation more broadly and tend to produce larger improvements in lung function. Montelukast is typically positioned as an alternative for patients who cannot tolerate or struggle to adhere to inhaled therapy, or as an add-on when inhalers alone are not enough.⁴

Adding Montelukast to an Existing Inhaler Regimen

For people already on inhaled corticosteroids who still have symptoms, adding montelukast can push their asthma toward better control. In a large open-label study of over 1,600 adults whose asthma was inadequately controlled on inhaled corticosteroids, with or without a long-acting bronchodilator, adding daily montelukast raised the average Asthma Control Test score from the “uncontrolled” range to nearly the “well-controlled” threshold over six months.⁵ A Canadian trial found that about three-quarters of patients whose asthma was uncontrolled at baseline reached guideline-defined control after eight weeks of add-on montelukast.⁶

The add-on approach is especially appealing for patients who have both asthma and allergic rhinitis, since montelukast addresses both at once. The RADAR trial specifically enrolled people with both conditions and found clinically meaningful improvement in rhinitis symptoms alongside the asthma gains.

Acute Asthma Flare-Ups

Although montelukast is mainly a maintenance drug, a randomized trial tested whether giving it on top of standard emergency treatment during an acute asthma flare-up could speed recovery. The answer was modestly yes. Patients who received montelukast in addition to the usual emergency care had significantly better peak airflow the morning after admission compared with those who got a placebo.⁷ This is not standard practice everywhere, and montelukast still should not replace corticosteroids or bronchodilators in an emergency. But the trial suggests it may offer a small extra push toward faster recovery.

Allergic Rhinitis

Leukotrienes play a role in the stuffy nose, sneezing, and itchy eyes that come with hay fever, so blocking them helps there too. Montelukast is approved for both seasonal allergic rhinitis, the kind that flares up in spring or fall, and perennial allergic rhinitis, the year-round variety triggered by dust mites or pet dander.

In seasonal allergic rhinitis, a large randomized trial found that montelukast reduced daytime nasal symptom scores significantly compared with placebo, and the improvement was comparable to what an antihistamine like loratadine achieved.⁸ Night symptoms and eye symptoms also improved. For perennial allergic rhinitis, a separate trial confirmed that montelukast produced steady, persistent improvement in nasal congestion, sneezing, rhinorrhea, and itching over six weeks of treatment.⁹

A review of the literature found that montelukast used alone for allergic rhinitis provides relief on par with antihistamines, but falls short of intranasal corticosteroid sprays. Combining montelukast with an antihistamine, however, can match the benefit of a nasal steroid spray.¹⁰ So if you are someone who hates nasal sprays, that combination might be a reasonable workaround.

Exercise-Induced Bronchoconstriction

Some people get tight, wheezy airways during or shortly after vigorous exercise even if their asthma is otherwise mild. Montelukast is one of the go-to preventive options for this. A landmark trial published in the New England Journal of Medicine found that after 12 weeks of daily montelukast, the post-exercise drop in lung function was reduced by about 47% compared with placebo.¹¹ In children, even a single dose before exercise significantly blunted the airway narrowing, and the protective effect lasted through 24 hours.¹²

One important caveat: not everyone responds. A study looking at the time course of montelukast’s protective effect confirmed that it worked from the first through the eighth hour after the first dose, but some individuals showed no protection at any time point.¹³ If you try it for exercise-related symptoms and it does nothing, that does not mean you are doing something wrong. It may simply not be the right drug for your particular biology.

Aspirin-Exacerbated Respiratory Disease

There is a condition sometimes called Samter’s triad: asthma, nasal polyps, and a worsening of both when you take aspirin or other NSAIDs. It is now more commonly called aspirin-exacerbated respiratory disease, or AERD. Leukotrienes are dramatically overproduced in this condition, which makes montelukast an especially logical fit. Studies have found that adding montelukast to the treatment plan for AERD improves asthma control, lung function, and nasal symptoms.¹⁴ It is not a cure, and many AERD patients need multiple overlapping therapies, but montelukast often becomes a mainstay in their regimen.

Chronic Urticaria (Hives)

Montelukast is sometimes prescribed off-label for chronic hives that do not respond well to antihistamines alone. A review of the evidence concluded that adding montelukast to antihistamine therapy is effective for patients whose hives resist antihistamines on their own.¹⁵ However, an earlier placebo-controlled crossover study of 22 patients found that montelukast did not significantly outperform placebo overall. The benefit was concentrated in the patients with the most severe hives.¹⁶ In other words, if your hives are moderate and already somewhat managed with antihistamines, adding montelukast may not move the needle. If your hives are severe and resistant to antihistamines, it is more likely to help.

Atopic Dermatitis

Because leukotrienes contribute to allergic inflammation in the skin as well as the airways, doctors have tried montelukast for atopic dermatitis (eczema). The results are mixed. A systematic review found that some studies showed improvements in itching and skin severity, while others found no benefit at all.¹⁷ A more recent meta-analysis across 26 studies added some nuance: montelukast did not significantly reduce eczema severity overall, but when the analysis was limited to adults specifically, there was a meaningful reduction.¹⁸ So it may be a reasonable option for some adults with moderate-to-severe eczema who have not responded to standard treatments, but the evidence is still thin enough that most dermatologists would not reach for it first.

The FDA’s Black Box Warning

In March 2020, the U.S. Food and Drug Administration added a boxed warning to montelukast, the most serious type of drug safety alert, citing reports of neuropsychiatric side effects including agitation, depression, sleep disturbances, and, rarely, suicidal thoughts and behavior.¹⁹ The FDA also stated that montelukast should be reserved for patients whose asthma or allergies cannot be adequately managed with other therapies, particularly when the indication is allergic rhinitis, since alternative treatments abound.

How common are these side effects in practice? A systematic review acknowledged the FDA’s concern but noted that age-related differences in risk remain largely unknown.²⁰ The reports that triggered the warning came mostly from the FDA’s voluntary adverse-event reporting system, which captures signals but cannot tell you how often something actually happens in a given number of users. Still, the warning had a concrete effect on prescribing patterns. After the boxed warning went into effect, monthly new prescriptions for montelukast dropped measurably, and the overall prevalence of montelukast use began declining at a faster pace than before.²¹

If you are currently taking montelukast and feeling fine, this does not mean you need to stop. The warning is a signal for you and your doctor to weigh the benefits against the risks and to stay alert for mood or behavior changes. If you notice new sleep problems, anxiety, unusual irritability, or depressed mood after starting montelukast, contact your prescriber.

Why Some People Respond and Others Do Not

One of the frustrating things about montelukast is that individual responses vary a lot. Some patients notice a dramatic improvement; others feel nothing. Part of the explanation is genetic. Variations in genes that code for enzymes and transporters in the leukotriene pathway can influence how much benefit a person gets. A study looking at several of these genes found that specific variants in the ALOX5 gene and in the LTC4S gene were associated with differences in lung function improvement and exacerbation rates on montelukast.²² Another study confirmed that ALOX5 promoter variants have a clear influence on montelukast response in people with moderate persistent asthma.²³

Even the same genetic variant may predict response differently depending on ethnic background. A meta-analysis found that a variant in the LTA4H gene was significantly associated with asthma exacerbations in European cohorts, but when Latino and African American populations were included, the association disappeared.²⁴ The hope is that someday a simple genetic test could predict who will benefit from montelukast before they spend weeks or months trying it. For now, the practical approach is trial and error: try it, evaluate after a few weeks, and stop if it is not helping.

Adherence and the Pill Versus Inhaler Advantage

One underappreciated advantage of montelukast is that it is a pill (or chewable tablet for kids), taken once daily. Inhalers require proper technique, coordination of breathing and actuation, and consistent twice-daily use for controllers. That matters in the real world. A study comparing adherence to montelukast versus inhaled fluticasone in children found median adherence of about 59% for montelukast versus 44% for fluticasone. Children on the inhaler were twice as likely to have very poor adherence as those on the pill.²⁵

A second study using pharmacy refill data found a smaller gap, with about 71% adherence for montelukast and 67% for inhaled corticosteroids, a difference that was not statistically significant.²⁶ Both studies agreed on one thing: adherence to either drug was well below ideal. The take-home is that a pill you actually take every day may control asthma better than an inhaler that sits in a drawer, even if the inhaler is theoretically the stronger medicine.

Cost Considerations

Montelukast went generic in 2012, which drove prices down substantially. Even so, cost-effectiveness analyses from the pre-generic era, when montelukast was still brand-name Singulair, generally found that inhaled corticosteroids like fluticasone were both more effective and less expensive. In a pediatric trial, total direct costs over 48 weeks were roughly $760 for fluticasone versus about $1,190 for montelukast.²⁷ A separate analysis from the Mexican health-care system found that combination inhalers were both cheaper and more effective than montelukast for controlling pediatric asthma.²⁸ With generic pricing, the cost gap has narrowed, but inhaled corticosteroids are also available generically now. The economic picture depends heavily on your insurance plan, your country’s drug pricing, and which specific products you are comparing.

Pediatric Dosing and Young Children with Wheeze

Montelukast comes in three dose tiers by age: 4 mg granules or chewable tablets for children ages 2 to 5, 5 mg chewable tablets for ages 6 to 14, and the standard 10 mg film-coated tablet for adolescents 15 and older and adults. A trial in children with intermittent asthma triggered by viral infections found that a short course of montelukast significantly reduced coughing, nighttime awakenings, time off school, and rescue inhaler use compared with placebo.²⁹

For preschoolers with recurrent wheezing episodes, however, the picture is murkier. A large U.K.-based trial gave intermittent montelukast to children between 10 months and 5 years old at the onset of wheezing episodes and found no significant reduction in unscheduled medical visits in the group as a whole. In a pre-specified subgroup of children whose parents were both positive for atopic disease, there was a reduction, but that benefit did not extend to the broader population.³⁰ So in very young children, montelukast should not be treated as a blanket solution for wheezing.

Early Research on Brain Health

An emerging and genuinely surprising area of montelukast research involves the brain. The leukotriene receptors montelukast blocks are not limited to the lungs. They exist in brain tissue too, and neuroinflammation driven by leukotrienes has been implicated in neurodegenerative diseases. In lab studies, montelukast protected neurons against toxicity from amyloid-beta, the protein fragment that accumulates in Alzheimer’s disease. It reduced markers of inflammation and cell death in cultured neurons exposed to amyloid-beta.³¹ In mice, repeated treatment with montelukast improved memory impairment caused by amyloid-beta injections and reduced neuroinflammation in the hippocampus and cortex.³²

Translating this to humans is a long way off. One challenge is that montelukast does not cross the blood-brain barrier very efficiently in its current oral formulations, which limits how much of the drug actually reaches the brain.³³ Researchers are exploring targeted delivery systems that could improve brain uptake, but no human trial has demonstrated cognitive benefits. The preclinical work is interesting enough to keep an eye on, but it would be premature to take montelukast expecting it to protect your brain.